However, one of the biggest challenges in designing and implementing controlled trials in NAFLD is the lack of consensus on appropriate end‐points for assessing the benefit of GLP‐1 RAs for NAFLD.24, 25. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.